{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:11Z","timestamp":1793662091424,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gerald G. and Dorothy R. Freidman New York Foundation for Medical Research"},{"name":"Empire Clinical Research Investigation Program of the New York State Department of Health"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.metop.2020.100050","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T10:39:00Z","timestamp":1597574340000},"page":"100050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Glycosylated hemoglobin, but not advanced glycation end products, predicts severity of coronary artery disease in patients with or without diabetes"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-1394","authenticated-orcid":false,"given":"Craig","family":"Basman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimiter","family":"Avtanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arber","family":"Kodra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume J.","family":"Stoffels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-5739","authenticated-orcid":false,"given":"Martin","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-8968","authenticated-orcid":false,"given":"Damian","family":"Inlall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Ziskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Poretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.metop.2020.100050_bib1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"NEJM"},{"issue":"24","key":"10.1016\/j.metop.2020.100050_bib2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Advance Collaborative Group","year":"2008","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.metop.2020.100050_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"NEJM"},{"issue":"15","key":"10.1016\/j.metop.2020.100050_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"NEJM"},{"key":"10.1016\/j.metop.2020.100050_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1476-511X-13-89","article-title":"Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina","volume":"13","author":"Hong","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"7","key":"10.1016\/j.metop.2020.100050_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2014.03.017","article-title":"Hemoglobin A1c in nondiabetic patients: an independent predictor of coronary artery disease and its severity","volume":"89","author":"Garg","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.metop.2020.100050_bib7","first-page":"267","article-title":"Advanced glycation end products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P)H-oxidase","volume":"45","author":"Tada","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metop.2020.100050_bib8","article-title":"The role of AGE\/RAGE signaling in diabetes-mediated vascular calcification","volume":"2016","author":"Kay","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"issue":"20","key":"10.1016\/j.metop.2020.100050_bib9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","article-title":"Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications","volume":"318","author":"Brownlee","year":"1988","journal-title":"NEJM"},{"issue":"5","key":"10.1016\/j.metop.2020.100050_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00003495-200464050-00001","article-title":"Advanced glycation end product crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease","volume":"64","author":"Zieman","year":"2004","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.metop.2020.100050_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CRD.0b013e318244e57c","article-title":"Advanced glycation end products and diabetic cardiovascular disease","volume":"20","author":"Prasad","year":"2012","journal-title":"Cardiol Rev"},{"issue":"2","key":"10.1016\/j.metop.2020.100050_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc10-1087","article-title":"Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes A 12-year follow-up study","volume":"34","author":"Nin","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metop.2020.100050_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/heart.85.1.87","article-title":"Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients","volume":"85","author":"Kiuchi","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.metop.2020.100050_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4070\/kcj.2012.42.5.335","article-title":"High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patients","volume":"42","author":"Won","year":"2012","journal-title":"Kor Circ J"},{"key":"10.1016\/j.metop.2020.100050_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1475-2840-10-98","article-title":"Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis","volume":"10","author":"Liu","year":"2011","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.metop.2020.100050_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.thromres.2014.07.008","article-title":"Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease","volume":"134","author":"Kerkeni","year":"2014","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.metop.2020.100050_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.metop.2020.100050_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(13)60108-7","article-title":"Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX Score II","volume":"381","author":"Farooq","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.metop.2020.100050_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MCA.0b013e3282fec058","article-title":"Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting","volume":"19","author":"Basta","year":"2008","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.metop.2020.100050_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.atherosclerosis.2013.01.016","article-title":"Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes","volume":"227","author":"Fujisawa","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metop.2020.100050_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.medici.2016.02.001","article-title":"N-caroxymethllysine as a biomarker for coronary artery disease and age-related macular degeneration","volume":"52","author":"Stanislovatiene","year":"2016","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.metop.2020.100050_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF03325227","article-title":"Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women","volume":"21","author":"Semba","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.metop.2020.100050_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijcard.2015.06.003","article-title":"Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease","volume":"197","author":"Yang","year":"2015","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.metop.2020.100050_bib24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1681\/ASN.V991681","article-title":"Plasma levels of pentosidine in diabetic patients: an advanced glycation end product","volume":"9","author":"Sugiyama","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.metop.2020.100050_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-0033-1363423","article-title":"Low levels of serum soluble receptor for advanced glycation endproducts, biomarkers for disease state: myth or reality","volume":"23","author":"Prasad","year":"2014","journal-title":"Int J Angiol"},{"issue":"9","key":"10.1016\/j.metop.2020.100050_bib26","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2337\/db11-0291","article-title":"Total solube and endogeous secretory receptor for advanced glycation endproducts as biomarkers of coronary heart disease risk in patients with type 2 diabetes","volume":"60","author":"Colhoun","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metop.2020.100050_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3132\/dvdr.2008.030","article-title":"Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease","volume":"5","author":"Saleem","year":"2008","journal-title":"Diabetes Vasc Dis Res"},{"issue":"3","key":"10.1016\/j.metop.2020.100050_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ahj.2007.04.057","article-title":"Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction","volume":"154","author":"Gustafsson","year":"2007","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.metop.2020.100050_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MCA.0b013e328342c760","article-title":"Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction","volume":"22","author":"Cicek","year":"2011","journal-title":"Coron Artery Dis"},{"issue":"1","key":"10.1016\/j.metop.2020.100050_bib30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2337\/dc18-1712","article-title":"Mendelian randomization analysis of hemoglobin A1c as a risk factor for coronary artery disease","volume":"42","author":"Leong","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metop.2020.100050_bib31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2337\/dci19-0023","article-title":"The cardiovascular legacy of good glycemic control: clues about mediators from the DCCT\/EDIC study","volume":"42","author":"Riddle","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metop.2020.100050_bib32","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1161\/01.CIR.91.9.2488","article-title":"Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics","volume":"91","author":"Berliner","year":"1995","journal-title":"Circulation"},{"issue":"9841","key":"10.1016\/j.metop.2020.100050_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists\u2019 Collaborators","year":"2012","journal-title":"Lancet"},{"issue":"9602","key":"10.1016\/j.metop.2020.100050_bib34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Prospective Studies Collaboration","year":"2007","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.metop.2020.100050_bib35","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Emerging Risk Factors","year":"2012","journal-title":"J\u00a0Am Med Assoc"},{"issue":"9753","key":"10.1016\/j.metop.2020.100050_bib36","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.metop.2020.100050_bib37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ekir.2017.11.009","article-title":"Glycated albumin versus HbA1c in the evaluation of glycemic control in patients with diabetes and CKD","volume":"3","author":"Gan","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.metop.2020.100050_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1172\/JCI117296","article-title":"Nonenzymatic glycosylation in\u00a0vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes","volume":"94","author":"Giardino","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.metop.2020.100050_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2016.10.012","article-title":"Advanced glycation end products: an emerging biomarker for adverse outcome in patients with peripheral artery disease","volume":"254","author":"De Vos","year":"2016","journal-title":"Atheroclerosis"},{"issue":"1","key":"10.1016\/j.metop.2020.100050_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10020-018-0060-3","article-title":"The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review","volume":"24","author":"Fishman","year":"2018","journal-title":"Mol Med"},{"issue":"6","key":"10.1016\/j.metop.2020.100050_bib41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jada.2010.03.018","article-title":"Advanced glycation end products in foods and a practical guide to their reduction in the diet","volume":"110","author":"Uribarri","year":"2010","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"8","key":"10.1016\/j.metop.2020.100050_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1631\/jzus.B1101004","article-title":"Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats","volume":"12","author":"Lu","year":"2011","journal-title":"J\u00a0Zhejiang Univ Sci B"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258993682030030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258993682030030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:54:35Z","timestamp":1762905275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258993682030030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"alternative-id":["S258993682030030X"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2020.100050","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycosylated hemoglobin, but not advanced glycation end products, predicts severity of coronary artery disease in patients with or without diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2020.100050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100050"}}